842 related articles for article (PubMed ID: 11496242)
21. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
22. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
23. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
24. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.
Kips JC; O'Connor BJ; Langley SJ; Woodcock A; Kerstjens HA; Postma DS; Danzig M; Cuss F; Pauwels RA
Am J Respir Crit Care Med; 2003 Jun; 167(12):1655-9. PubMed ID: 12649124
[TBL] [Abstract][Full Text] [Related]
25. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9.
Sitkauskiene B; Rådinger M; Bossios A; Johansson AK; Sakalauskas R; Lötvall J
Respir Res; 2005 Apr; 6(1):33. PubMed ID: 15823208
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
27. The trials and tribulations of IL-5, eosinophils, and allergic asthma.
O'Byrne PM; Inman MD; Parameswaran K
J Allergy Clin Immunol; 2001 Oct; 108(4):503-8. PubMed ID: 11590372
[TBL] [Abstract][Full Text] [Related]
28. Effects of an antibody to interleukin-5 in a monkey model of asthma.
Mauser PJ; Pitman AM; Fernandez X; Foran SK; Adams GK; Kreutner W; Egan RW; Chapman RW
Am J Respir Crit Care Med; 1995 Aug; 152(2):467-72. PubMed ID: 7633694
[TBL] [Abstract][Full Text] [Related]
29. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation.
Garlisi CG; Kung TT; Wang P; Minnicozzi M; Umland SP; Chapman RW; Stelts D; Crawley Y; Falcone A; Myers JG; Jones H; Billah MM; Kreutner W; Egan RW
Am J Respir Cell Mol Biol; 1999 Feb; 20(2):248-55. PubMed ID: 9922215
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
31. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients.
Oldhoff JM; Darsow U; Werfel T; Bihari IC; Katzer K; Laifaoui J; Plötz S; Kapp A; Knol EF; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
Int Arch Allergy Immunol; 2006; 141(3):290-4. PubMed ID: 16931891
[TBL] [Abstract][Full Text] [Related]
32. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
[TBL] [Abstract][Full Text] [Related]
33. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354).
Blanchard C; Mishra A; Saito-Akei H; Monk P; Anderson I; Rothenberg ME
Clin Exp Allergy; 2005 Aug; 35(8):1096-103. PubMed ID: 16120093
[TBL] [Abstract][Full Text] [Related]
37. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
38. Narirutin inhibits airway inflammation in an allergic mouse model.
Funaguchi N; Ohno Y; La BL; Asai T; Yuhgetsu H; Sawada M; Takemura G; Minatoguchi S; Fujiwara T; Fujiwara H
Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):766-70. PubMed ID: 17600554
[TBL] [Abstract][Full Text] [Related]
39. Prolonged eosinophil production after allergen exposure in IFN-gammaR KO mice is IL-5 dependent.
Zhao LL; Lötvall J; Lindén A; Tomaki M; Sjöstrand M; Bossios A
Scand J Immunol; 2008 May; 67(5):480-8. PubMed ID: 18405326
[TBL] [Abstract][Full Text] [Related]
40. Chemokine receptor 2 blockade prevents asthma in a cynomolgus monkey model.
Mellado M; Martín de Ana A; Gómez L; Martínez C; Rodríguez-Frade JM
J Pharmacol Exp Ther; 2008 Feb; 324(2):769-75. PubMed ID: 18029547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
